Get the Stockscreener App
143.31
0.19%
-0.28
After Hours:
143.31
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $143.31, with a volume of 2.86M.
It is down -0.19% in the last 24 hours and up +14.88% over the past month.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
See More
Previous Close:
$143.59
Open:
$143.12
24h Volume:
2.86M
Relative Volume:
1.90
Market Cap:
$15.99B
Revenue:
$2.90B
Net Income/Loss:
$239.11M
P/E Ratio:
67.93
EPS:
2.1097
Net Cash Flow:
$492.62M
1W Performance:
+2.23%
1M Performance:
+14.88%
6M Performance:
+66.76%
1Y Performance:
+66.12%
1-Day Range:
$141.71
$144.77
1-Week Range:
$140.20
$149.52
52-Week Range:
$81.22
$149.52
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
143.31 | 13.87B | 2.90B | 239.11M | 492.62M | 2.1097 |
TMO
Thermo Fisher Scientific Inc
|
658.52 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
221.09 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
390.90 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
167.26 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
270.09 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-25 | Initiated | Goldman | Neutral |
| Oct-16-25 | Initiated | Guggenheim | Neutral |
| May-01-25 | Upgrade | UBS | Neutral → Buy |
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
(RVTY) Volatility Zones as Tactical Triggers - Stock Traders Daily
Revvity Inc Share PriceRVTY, RNS News, Articles, Quotes, & Charts (NYSE:RVTY) - Proactive financial news
Revvity, Inc. rStock (RRVTY) Price Prediction for 2026 to 2031 - bybit.com
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery - Yahoo Finance
Revvity Inc. stock gains momentum as UBS adjusts price target and Q2 2026 revenue edges higher - ad-hoc-news.de
Top Revvity (RVTY) Competitors 2026 - MarketBeat
Revvity stock heads into the open after a 2.35% slide - ad-hoc-news.de
Revvity Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Revvity (RVTY) Receives a New Rating from UBS - The Globe and Mail
Revvity stock heads into the open after a 2.5% Nasdaq drop - ad-hoc-news.de
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Revvity, Inc. entered into a definitive agreement to acquire Human Cell Design SAS. - marketscreener.com
Revvity to acquire Human Cell Design for metabolic research tools By Investing.com - Investing.com Australia
RVTY Assumes Rating by UBS -- Price Target Raised to $140 - GuruFocus
Revvity at Wells Fargo 21st annual healthcare conference: growth and margin focus - Investing.com India
Revvity Acquiring French Firm Human Cell Design - GenomeWeb
Revvity Bets on GLP-1 Boom With Human Cell Design Acquisition - Benzinga
UBS Downgrades Revvity to Neutral From Buy, Adjusts Price Target to $140 From $120 - marketscreener.com
Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery - BioSpace
Revvity, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
RVTY Looks 8.1% Overvalued on GF Value™ - GuruFocus
RVTY Looks 8.1% Overvalued on GF Value™ as Acquisition Adds Grow - GuruFocus
Revvity to Acquire Human Cell Design - marketscreener.com
Revvity to acquire Human Cell Design - TradingView
Revvity to acquire Human Cell Design for metabolic research tools - investing.com
A planned Revvity deal would add human pancreatic cells for diabetes research - Stock Titan
Revvity Inc. stock slips despite solid Q2 2026 growth and cautious analyst outlook - ad-hoc-news.de
Revvity stock heads into the open after a 2.1 percent drop - ad-hoc-news.de
Revvity Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
T. Rowe Price controls over 10M Revvity (NYSE: RVTY) shares, with one fund holding about half the stake - Stock Titan
Revvity Inc. stock holds above 130 dollars as analysts stick with Hold ratings - ad-hoc-news.de
Revvity, Inc. (RVTY) Stock Analysis: Navigating Potential in the Diagnostics Sector Amid Mixed Ratings - DirectorsTalk Interviews
KeyBanc Maintains Revvity(RVTY.US) With Buy Rating, Raises Target Price to $165 - Moomoo
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich? - Yahoo Finance
KeyBanc Adjusts Price Target on Revvity to $165 From $125, Maintains Overweight Rating - marketscreener.com
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Revvity Inc. stock holds near 52-week high as valuation debate intensifies - AD HOC NEWS
Baird Adjusts Price Target on Revvity to $144 From $131, Keeps Outperform Rating - marketscreener.com
Revvity (RVTY) Stock Looks Fair On Cash Flow Yet Pricey On Earnings - finance.yahoo.com
Revvity Inc (RVTY) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 77/100 - GuruFocus
Revvity (RVTY) Margins Story Faces A Valuation Test Following Its Zacks Upgrade - Yahoo Finance
What Makes Revvity (RVTY) a New Buy Stock - finance.yahoo.com
Revvity Faces Growth Challenges Amid Rising Competition, RBC Says - marketscreener.com
RBC Initiates Revvity at Sector Perform With $135 Price Target - marketscreener.com
RBC Capital initiates Revvity stock with Sector Perform rating By Investing.com - Investing.com Australia
RBC Capital initiates Revvity stock with Sector Perform rating - investing.com
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
Revvity, Inc. (RVTY) Stock Analysis: Navigating a 6% Potential Downside with Strategic Insights - DirectorsTalk Interviews
Revvity (RVTY) Eases to $128.8: Key Support at $122.36 Holds in FocusImbalance Zone - vinanet.vn
Revvity Inc stock hits 52-week high at 130.07 USD By Investing.com - Investing.com Nigeria
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.13%
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):